BDBM517009 N-(3-fluoro-4-((3- (((2R,3R)-3- hydroxybutan-2- yl)amino)-1H- pyrazolo[3,4-b]pyridin-4- yl)oxy)phenyl)-3-(4- fluorophenyl)-1- isopropyl-2,4-dioxo- 1,2,3,4- tetrahydropyrimidine-5- carboxamide::US11104676, Example 79

SMILES C[C@@H](O)[C@@H](C)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c12

InChI Key InChIKey=WTICENLKVSJKNG-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 517009   

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 1.20E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 2.90E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 1.97E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 3.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 3.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 3.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 2.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 18.1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM517009(US11104676, Example 79 | N-(3-fluoro-4-((3- (((2R,...)
Affinity DataIC50: 2.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent